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LETTER TO THE EDITOR 
 
Gaq signaling is required for the maintenance of MLL-AF9 induced AML  
Self-renewal and differentiation block are two key features of leukemic stem cells (LSCs) in MLL-
rearranged AML, which can originate from either hematopoietic stem cells (HSCs) or granulocyte 
macrophage progenitors (GMPs). We have previously demonstrated that β-catenin is essential for the 
establishment of MLL LSCs, where MLL-AF9 activates β-catenin, one role of which is to confer self-
renewal capacity to GMPs necessary for malignant transformation (1). The effect of β-catenin appears to 
be largely context dependent and driven by its upstream components that fine-tune the signal to modulate 
different functional programs downstream of β-catenin (2). The targeting of critical upstream components 
could therefore serve as a potential strategy to effectively block β-catenin signaling. However, our 
understanding of upstream signaling events leading to β-catenin activation in leukemia still remains poor. 
 
G proteins and G protein-coupled receptors have been implicated in playing crucial roles in multiple 
cancers, where specific members of this family influence self-renewal and tumorigenesis largely through 
activation of β-catenin signaling (2). The G protein subunit Gaq has recently been identified as a direct 
target of MLL-AF4 (3), and Dot1l-mediated H3K79 methylation marks are enriched at the Gaq locus in 
MLL-AF9 LSCs (4), indicating a role for Gaq in MLL leukemia.  
 
To determine if Gaq is functionally important in MLL AML, we first examined the effects of Gaq 
inhibition on active β-catenin expression and colony-forming capacity of pre-LSCs derived from MLL-
AF9 transduced KLS (HSC-enriched Lin
-
 CD127
-
 Sca-1
+
 c-Kit
+
) and GMPs (Lin
-
 CD127
-
 Sca-1
-
 c-Kit
high
 
CD16/32
high
 CD34
+
) (1). These pre-LSCs are a recognized early stage of leukemia development that 
subsequently acquires additional events in vivo leading to a full-blown leukemia (1). Stable knockdown of 
Gaq in pre-LSCs was achieved by lentiviral-mediated delivery of short hairpin RNA (shGaq). We found 
that all three individual shGaq reduced Gaq expression in KLS-derived pre-LSCs (KLS
pre-LSC
) and GMP-
derived pre-LSCs (GMP
pre-LSC
) and as a result, Gaq knockdown led to a significant decrease in the levels 
of active β-catenin and colony formation (Figures 1a, 1b).  
 
We next explored the effect of pharmacological inhibition of Gaq on pre-LSCs and leukemic cells. In the 
presence of 40 µM GP antagonist 2A (GP), a selective inhibitory peptide of Gaq protein (5), KLS
pre-LSC
 
exhibited a significant decrease in β-catenin expression associated with a 50% reduction in colony 
formation (Figure 1c; Figure S1). We then assessed the antagonistic effects of GP on GFP
+
 leukemic 
cells sorted from fully developed primary MLL AML originating from KLS or GMPs (KLS/GMP
leukemic
). 
The inhibitory effects observed for KLS
pre-LSC
 and KLS
leukemic
 cells (Figures 1c, 1d) were similar while 
GMP
leukemic
 cells appeared to be more sensitive to GP treatment (Figure 1e).   
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We next tested the leukemogenic inhibitory potential of GP inhibition in vivo, by pre-treating leukemic 
cells ex vivo with GP (40uM) for 2 - 4 days, and subsequently transplanting viable cells into sub-lethally 
irradiated recipient mice. In vivo BrdU labeling analysis at 8 days post-injection showed that 2-day GP 
pre-treatment led to impaired cell proliferation in both KLS
leukemic
 and GMP
leukemic
 cells (Figures 1f, 1g).  
Consistent with the in vitro clonogenic assays (Figures 1d, 1e) we observed a slightly more pronounced 
reduction in proliferation for GMP
leukemic
 cells. Further survival analysis showed that 4-day GP pre-
treatment was able to promote a small but significant enhancement of survival in mice transplanted with 
GMP
leukemic
 cells (Figure 1h), and genetic depletion of Gaq also significantly delayed the onset of 
leukemia induced by GMP
leukemic
 cells (Figure 1i). Together, this provides the first evidence that Gaq 
signaling contributes to maintenance of fully-developed AML. Furthermore, we found that the inhibitory 
effect of GP on human MLL-AF9 AML cells might largely depend on the expression levels of 
endogenous β-catenin, as we observed that GP selectively suppressed the growth of human THP-1 AML 
cells (Figure 1j) that endogenously express β-catenin (6), but had no effects on MOLM-13 cells (Figure 
1j) as well as other human AML cell lines (e.g. ML2 carrying the MLL-AF6 translocation, data not 
shown) in which β-catenin expression is undetectable (6). In contrast, ABT-199, a selective Bcl2 inhibitor, 
had a β-catenin-independent effect and inhibited the growth of these AML cell lines (Figure 1j).      
 
In an attempt to dissect the mechanism by which Gaq inhibition causes impairment in MLL 
leukemogenesis, we performed gene-expression analysis using RNA from shGaq transduced KLS
leukemic
 
cells and found that several mitochondrial complex 1 genes (i.e. mt-Nd2, mt-Nd4l, mt-Nd5) were down-
regulated in Gaq knockdown cells, while the stress response and DNA damage repair gene Gadd45a was 
up-regulated (Figure 2a). The link between Gaq mRNA expression and the expression of 
mitochondrially-encoded Nd2 and Nd4l genes was confirmed in a panel of primary human AML samples 
(n = 84; Table S1). Furthermore, activation of Gadd45a has been shown to occur as a result of activation 
of the FoxO family of transcription factors in response to oxidative stress (7). Taken together, these data 
suggest a possible link between Gaq and mitochondrial function; therefore, we next sought to test whether 
Gaq inhibition affects the response of leukemic cells to mitochondrial stress. We first treated leukemic 
cells with the mitochondrial complex 1 inhibitor rotenone, which has been reported to increase ROS 
production triggering apoptosis (8). Our results showed that ROS levels were slightly elevated in 
rotenone-treated KLS
leukemic
 cells and were dramatically increased in rotenone-treated GMP
leukemic
 cells 
(Figure 2b). Gaq knockdown also dramatically increased ROS levels in GMP
leukemic
 cells (Figure 2c), 
suggesting a crucial role for Gaq activation in protecting GMP
leukemic
 cells against oxidative stress. Gaq 
activity is important in GMP
leukemic
 cells for maintaining basal oxidative phosphorylation (OXPHOS) 
levels and mitochondrial ATP production as Gaq inhibition, by either GP treatment or Gaq knockdown, 
significantly reduced the oxygen consumption rate (OCR, indicative of OXPHOS) and ATP levels in these 
cells, with a slightly reduced effect in KLS
leukemic
 cells (Figures 2d, 2e, 2f, 2g). Such a functional role for 
Gaq is in keeping with the positive correlation between expression of Gaq and levels of mitochondrial 
complex 1 gene expression, supporting the hypothesis that Gaq expression and function may be closely 
©    2016 Macmillan Publishers Limited. All rights reserved.
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coupled to mitochondrial function in AML cells. It is worth noting that in MLL leukemic cells Gaq 
inhibition had similar effects to rotenone treatment on induction of ROS and suppression of OCR and 
colony formation (Figures 2b, 2d, 2h).  
 
In this study, we report a previously unknown role for Gaq in maintenance of MLL leukemia. Previous 
studies implicate Gaq as a MLL fusion target whose expression correlates with H3K79 methylation in 
MLL LSCs (3, 4). The effect of Gaq inhibition on repression of MLL leukemic cell growth largely 
depends on endogenous β-catenin activity. This is consistent with our previous findings that aberrant 
activation of β-catenin is essential for self-renewal of MLL LSCs, whereas inhibition of β-catenin impairs 
LSC formation and MLL leukemia development (1, 9).  
 
Here we describe a potential mechanism linking mitochondrial function to leukemogenesis via Gaq 
signaling activation (Figure S2). LSCs in AML rely primarily on OXPHOS to generate ATP for energy 
(10), and our results show that Gaq inhibition can impair the energy-generating capacity of MLL leukemic 
cells, increase ROS levels and lead to activation of a stress response associated with activation of 
Gadd45a. Our data revealing reduced β-catenin levels following Gaq inhibition are consistent with the 
effects of Gaq on mitochondrial activity being mediated via β-catenin activity, as recent studies have 
shown the crucial role for β-catenin in mitochondrial energy metabolism (11, 12), and β-catenin is also 
critical in HSC for suppression of ROS levels (12). MLL AML has a particular dependence on β-catenin 
activity (1) and the findings presented here raise the possibility that targeting of -catenin and 
mitochondrial metabolism via Gaq may be a potential approach to reduction of leukemogenesis in MLL 
AML. Of note, while human AML represents a heterogeneous disease, the correlation of Gaq expression 
with expression of mitochondrially-encoded Nd2 and Nd4l genes provides support that Gaq-regulation of 
mitochondrial function may also be important in other AML subtypes. Whether activity of Gaq and/or 
OXPHOS in human AML cells, or levels of mitochondrial complex 1 genes, are predictive of response to 
chemotherapy is still under investigation. Gaq-mediated signaling is likely to cooperate with other 
pathways to drive leukemogenesis. In particular, FLT3-ITD mutation accelerates the onset of MLL-AF9-
induced AML and correlates with poor outcome in AML patients (13). We have previously demonstrated 
that down-regulation of Gadd45a via FLT3-ITD contributes to the myeloid differentiation block in AML 
(14), and strikingly the regulator of G protein signaling 2 (Rgs2), a potent negative regulator of Gaq 
function (15), has also been shown to be a critical target gene down-regulated in FLT3-ITD-induced AML 
(16). 
 
It is essential to investigate the mechanisms involved in G protein-associated regulation of β-catenin 
signaling in AML LSCs, as a number of studies have now shown that G-protein coupled signaling can be 
targeted therapeutically (15) and such an approach may provide clinical benefit for MLL AML patients. 
Future studies will identify predominant transducers in Gaq signaling and further define the role of -
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catenin down-regulation, FoxO transcription factors and Gadd45a in the stress response associated with 
Gaq inhibition.  
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Figure Legends 
 
Figure 1: Gaq is required for maintenance of MLL leukemia. 
(a) Western blot analysis of Gaq knockdown efficiency and β-catenin expression (total β-catenin versus 
phosphorylated/inactive β-catenin) in scrambled control (Scr) versus 3 independent Gaq shRNAs 
(shGaq#1, shGaq#2, shGaq#3) transduced KLS
pre-LSC
 and their respective colony formation. A reduced 
level of total β-catenin (β-cat) protein, concomitant with no change in phosphorylated/inactive β-catenin 
(p-β-cat), indicates the activation of β-catenin. The percentage of colonies at the third round of replating is 
shown.   
(b) Western blot analysis of Gaq and β-catenin expression in Scr, shGaq#1, shGaq#2 or shGaq#3 
transduced GMP
pre-LSC
 and their respective colony formation. 
(c) Colony formation of KLS
pre-LSC
 treated with control (water, H2O), 20 µM GP or 40 µM GP for 5 days, 
and western blot analysis of β-catenin expression in KLSpre-LSC treated with 40 µM GP.  
(d, e) Colony formation of KLS
leukemic 
cells (d) or GMP
leukemic 
cells (e) treated with 20 µM GP or 40 µM 
GP for 5 days. *, P < 0.05; **, P < 0.01; ***, P < 0.0005; ****, P < 0.0001. 
(f, g, h) Bar graphs representing quantitative analysis of the data obtained from in vivo BrdU incorporation 
cell proliferation assays, indicative of 5 independent experiments for KLS
leukemic 
cells (f) and 6 independent 
experiments for GMP
leukemic 
cells (g). GFP
+
 leukemic cells, which were sorted from fully developed 
primary MLL AML originating from KLS or GMPs, were pre-treated ex vivo with 40 µM GP for 2 - 4 
days and subsequently transplanted into 2
nd
 recipient mice for in vivo BrdU cell proliferation assays at 8 
days post-injection (f, g), and Kaplan–Meier analysis of mouse survival (h).  
(i) Kaplan-Meier survival curves of mice transplanted with GMP
leukemic
 cells expressing Scr versus 
shGaq#2. 
©    2016 Macmillan Publishers Limited. All rights reserved.
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(j) Growth inhibition in human AML cell lines after treatment with 40 µM GP or 1 µM ABT-199 for 72 
hr, determined by AlamarBlue cell proliferation assay.  
**, P < 0.01; ***, P < 0.0005; ****, P < 0.0001; NS, not significant (P > 0.05). 
  
Figure 2: Gaq inhibition target leukemic cells by impairing mitochondrial OXPHOS.  
(a) Heat map showing differential expression of genes in Scr versus shGaq transduced KLS
leukemic
 cells 
(Blue = down-regulated, Red = up-regulated) with p-value ≤ 0.01 and fold change cutoff of  ≥ 1.9.  
(b, c) Mitochondrial ROS, as evaluated by the mitochondrial-specific redox probe MitoSox in KLS
leukemic
 
or GMP
leukemic
 cells treated with control (DMSO), 25 nM rotenone or 50 nM rotenone for 24 h (b), or 
transduced with Scr versus shGaq (c).  
(d, e) KLS
leukemic
 or GMP
leukemic
 cells treated with 40 µM GP or 1 µM rotenone for 48 h (d), or transduced 
with Scr versus shGaq (e). OCR was measured over a 2 h period and plotted as normalized % values of 
baseline (control) values for each sample.  
(f, g) ATP levels in KLS
leukemic
 or GMP
leukemic
 cells treated with 40 µM GP for 48 h (f), or transduced with 
Scr versus shGaq (g). 
(h) Colony formation of KLS
leukemic
 or GMP
leukemic
 cells treated with 25 nM rotenone or 50 nM rotenone 
for 5 days.   
©    2016 Macmillan Publishers Limited. All rights reserved.
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